Please provide your email address to receive an email when new articles are posted on . The clinical trials have purposefully strict inclusion and exclusion criteria to control the variables that ...
Due to an aging population, visual impairment from neovascular age-related macular degeneration (nAMD) is increasing in the United States. Despite unprecedented improvements in vision preservation ...
A randomized clinical trial, part of the Age-Related Eye Disease Study (AREDS) and led by the National Eye Institute, was conducted in order to try to evaluate the effect of antioxidants and zinc in ...
Background: With increasing experience using anti-VEGF therapy for the treatment of neovascular age-related macular degeneration (nAMD), ophthalmologists have shifted away from a "one size fits all" ...
TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase ...
brolucizumab Beovu 6mg/0.05mL soln for intravitreal inj 6mg (0.05mL) once monthly (approx. 25–31 days) for the 1st 3 doses, followed by 6mg (0.05mL) once every 8–12wks ranibizumab Lucentis 6mg/mL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results